Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies. by Rockenstein, Edward et al.
UC San Diego
UC San Diego Previously Published Works
Title
Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's 
disease and fronto-temporal tauopathies.
Permalink
https://escholarship.org/uc/item/6gk6h4hf
Journal
BMC neuroscience, 16(1)
ISSN
1471-2202
Authors
Rockenstein, Edward
Ubhi, Kiren
Mante, Michael
et al.
Publication Date
2015-11-26
DOI
10.1186/s12868-015-0218-7
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Rockenstein et al. BMC Neurosci  (2015) 16:85 
DOI 10.1186/s12868-015-0218-7
RESEARCH ARTICLE
Neuroprotective effects of Cerebrolysin 
in triple repeat Tau transgenic model of Pick’s 
disease and fronto-temporal tauopathies
Edward Rockenstein1, Kiren Ubhi1, Michael Mante1, Jazmin Florio1, Anthony Adame1, Stefan Winter2, 
Hemma Brandstaetter2, Dieter Meier2 and Eliezer Masliah1,3*
Abstract 
Background: Tauopathies are a group of neurodegenerative disorders with accumulation of three-repeat (3R) or 
four-repeat (4R) Tau. While 3R tau is found in Pick’s disease and Alzheimer’s disease (AD), 4R tau is more abundant in 
corticobasal degeneration, progressive supranuclear palsy, and AD. We have previously shown that Cerebrolysin™ 
(CBL), a neuropeptide mixture with neurotrophic effects, ameliorates the pathology in amyloid precursor protein 
transgenic (tg) mouse model of AD and 4R tau, however it is unclear if CBL ameliorates the deficits and neuropathol-
ogy in the mouse model of Pick’s disease over expressing 3R tau.
Results: Mice expressing 3R tau (L266V and G272V mutations) under the mThy-1 promoter were treated with CBL in 
two separate groups, the first was 3 months old (treated for 3 months, IP) and the second was 6 months old (treated 
for 3 months, IP) at the start of the treatment. We found that although the levels of total 3R tau were unchanged, CBL 
reduced the levels of hyper-phosphorylated tau in both groups of mice. This was accompanied by reduced neuro-
degenerative pathology in the neocortex and hippocampus in both groups and by improvements in the behavioral 
deficits in the nest-building test and water maze in the 3–6 month group.
Conclusion: Taken together these results support the notion that CBL may be beneficial in other taupathy models by 
reducing the levels of aberrantly phosphorylated tau.
Keywords: 3 repeat Tau, Pick’s disease, Cerebrolysin, Neuronal loss, Transgenic
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medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Tau is a major neuronal cytoskeletal protein encoded by 
an alternatively spliced gene (MAPT) present on chro-
mosome 17 (MAPT) [1]. Six different isoforms of tau are 
found in the CNS and, depending on the number of the 
~32 amino acid microtubule binding domain repeats, 
can be either three-repeat (3R) and four-repeat (4R) tau 
[2]. Taupathies are common neurodegenerative disorders 
of the aging population that lead to behavioral altera-
tions and dementia [3–5]. Tauopathies are divided into 
those containing 3R, 4R or both species of tau. While 
4R tau alone is predominantly present in corticobasal 
degeneration (CBD) and progressive supranuclear palsy 
(PSP) in Pick’s disease (PiD) only 3R tau accumulates. A 
mixture of 3R and 4R tau is found in Alzheimer’s Disease 
(AD) and FTDP-17T [3].
Pick’s disease is a rare neurodegenerative disorder asso-
ciated with dementia and fronto-temporal lobar degen-
eration [6]. Patients with PiD display cortical atrophy, 
neuronal loss, astrogliosis and formation of 3R tau-pos-
itive, globular, intra-neuronal inclusions in the neocortex 
and limbic system denominated pick bodies (PBs) [3]. 
There are sporadic and familial forms and mutations in 
MAPT account for the majority of these cases [7–10].
Cerebrolysin™ (CBL) is a peptide mixture with neuro-
trophic-like properties that amliorates behavioral defi-
cits in patients with mild to moderate AD [11]. Likewise, 
we have previously shown that CBL ameliorates the 
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neurodegenerative pathology in amyloid precursor pro-
tein (APP) transgenic (tg) models of AD [12–15] as well 
as in models of tauopathy expressing 4R tau [16, 17]. The 
protective effects of CBL in these models of AD and tau-
pathy might involve different mechanisms including reg-
ulation of GSK3β and CDK5 signaling and anti-apoptotic 
effects mediated by expression of endogenous neuro-
trophic factors [18]. However, it is unclear if CBL might 
display similar neuroprotective effects in models of 3R 
tau accumulation that mimic PiD.
We recently developed a tg mouse model expressing 3R 
tau bearing mutations associated with familial forms of 
PiD (L266V and G272V) under the neuronal mThy-1 pro-
moter [19]. These mice display extensive time-dependent 
accumulation of 3R tau in the neocortex and hippocam-
pus, with inclusion formation, behavioral deficits, and 
neurodegeneration that mimic some aspects of PiD [19]. 
In the present study, these 3R tau tg mice were treated 
with CBL starting at 3 month old (for 3 month, IP) or at 
6 months of age (for 3 month, IP) and evaluated neuro-
pathologically and behaviorally. We found that although 
total levels of 3R tau were unchanged, CBL reduced the 
levels of hyper-phosphorylated tau in both groups of 
mice. This was accompanied by reductions in the neuro-
degenerative pathology in both groups and by improve-
ments in the behavioral deficits in the younger group. 
Taken together these results suggest that CBL might be 
beneficial in orphan disease tauopathies such as PiD.
Methods
Generation of mThy‑1 3R Tau mutant transgenic mice 
and treatments
All animal experiments were approved by The University 
of California at San Diego’s animal subjects committee. 
Mice expressing human 3R Tau-bearing the mutations 
associated with familial PiD (L266V and G272V) under 
the neuronal mThy-1 promoter cassette (provided by 
Dr. H. van der Putten) were generated on the C57BL/6 
background, as previously described [19]. The high 
expressing Line 13 mice were chosen for these studies. 
To differentiate preventative versus therapeutic effects 
of CBL, the mice were divided into two groups, the first 
were 3  months old at the start of the experiment and 
were treated for 3 months (IP, 5 ml/kg) with CBL or vehi-
cle (n = 10 per group). This group is hereafter denomi-
nated as the “3–6 month” group. The second group was 
6 months old at the beginning of the experiment and was 
treated for 3  months (IP, 5  ml/kg) with CBL or vehicle 
(n = 10 per group). This group is hereafter denominated 
as the “6–9 month” group. For both groups, control, non-
tg littermates of the same age and gender were included 
and treated with either vehicle or CBL (IP, 5  ml/kg) for 
3  months (n  =  10 per group). A total of 80 mice (40 
non-tg and 40 tg) were included in this study. Mice were 
killed 24 h after the last injection of vehicle or CBL was 
administered. Cerebrolysin is a mixture of peptides and 
amino acids obtained after high quality hydrolyzing and 
purification from porcine brain, more information is 
available at the web site (http://www.hypermed.com.au/
Clinical%20Research/EVER2010_Monograph_screen.
pdf). Cerebrolysin was a gift from EverPharma.
Behavioral analysis
One month prior to the end of the experiments, mice 
were tested in the behavioral paradigms. Mice were 
continued with vehicle or CBL during the course of the 
testing. Spatial learning and memory was investigated 
using the water maze. For this purpose, a pool (diameter 
180  cm) was filled with opaque water (24  °C) and mice 
were first trained to locate a visible platform (days 1–3) 
and then a submerged hidden platform (days 4–7) in 
three daily trials 2–3 min apart. Mice that failed to find 
the hidden platform within 90  s were placed on it for 
30 s. The same platform location was used for all sessions 
and all mice. The starting point at which each mouse was 
placed into the water was changed randomly between 
two alternative entry points located at a similar distance 
from the platform. In addition, on the final day of test-
ing the platform was removed and the time spent by 
mice in the correct quadrant was measured (Probe test). 
The duration of the probe test was 40  s. Time to reach 
the platform (escape latency) was recorded with a Nol-
dus Instruments EthoVision video tracking system (San 
Diego Instruments, San Diego, CA) set to analyze two 
samples per second. The nesting test and open field was 
performed in plastic cages with beam break photodetec-
tors as previously described [20].
Tissue preparation
Following behavioral analysis, mice were killed following 
NIH guidelines. The right hemi-brain was post-fixed for 
48  h in 4  % phosphate-buffered paraformaldehyde (pH 
7.4) at 4 °C and sagittal sectioned vibratome 2000 (40 µm 
Leica, Deerfield, IL). The left hemi-brain was snap-frozen 
and stored at −70 °C.
Immunohistochemistry and image analysis
Analysis of tau expression was performed using free-
floating, blind-coded vibratome (50  µm thick) sections 
[21]. Sections were incubated overnight at 4 °C with anti-
bodies against 3R tau (1:250, Millipore) and pTau (PHF-1 
1:500, gift from Peter Davies) followed by biotin-tagged 
anti-rabbit or anti-mouse IgG1 secondary antibodies 
(1:100, Vector Laboratories, Inc., Burlingame, CA), Avi-
din D-HRP (1:200, ABC Elite, Vector), and visualized 
with diaminobenzidine. Sections were scanned with a 
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digital Olympus bright field digital microscope (BX41). 
For comparison of the neuropathological pathology in 
human PiD samples with the 3R tau mice, samples from 
the frontal cortex from three PiD cases were obtained 
from patients evaluated neurologically and psychometri-
cally at the Alzheimer Disease Research Center/Univer-
sity of California, San Diego [22].
Neurodegenerative pathology was analyzed using sec-
tions immunolabeled overnight with antibodies against 
the neuronal marker NeuN (1:500, Millipore) and the 
astroglial marker glial fibrillary acidic protein (GFAP, 
1:1000, Millipore). Sections reacted with antibodies 
against NeuN or GFAP were incubated with secondary 
antibodies, Avidin D-HRP, and visualized with diamin-
obenzidine. Analysis of levels of Tau and GFAP immu-
noreactivity was performed in layer 5 of the neocortex 
and in the hippocampus dentate gyrus with Image J and 
expressed as optical density. Briefly, for each section 
a total of four images were captured at 400× and con-
verted to gray scale, opened with Image J, thresholded 
and a dynamic scale set to determine optical density. 
The numbers of NeuN-immunoreactive neurons were 
estimated utilizing unbiased stereological methods [23]. 
Hemi-sections containing the neocortex, hippocampus 
and striatum were outlined using an Olympus BX51 
microscope running StereoInvestigator 8.21.1 software 
(Micro-BrightField, Cochester, VT). Grid size for the 
hippocampal dentate was: 300 × 300 µm, and the count-
ing frame was 50  ×  50  µm. The average coefficient of 
error for each region was 0.09. Sections were analyzed 
using a 100  ×  1.4 PlanApo oil-immersion objective. A 
5  µm high dissector, allowed for 2  µm top and bottom 
guard-zones.
Tissue fractionation and immunoblot analysis
The levels of tau were analyzed using lysates that were 
extracted and fractioned into soluble and insoluble frac-
tions by ultracentrifugation utilizing the posterior half 
of the right hemi-brain that includes the neocortex and 
hippocampus [20]. Protein (20 µg/lane) from the insolu-
ble fraction was loaded onto 4–12  % SDS/PAGE gels 
and blotted onto PVDF membranes, incubated mouse 
monoclonal antibodies against total Tau (tTau 1:1000), 
3R tau (1:2000), p-tau (PHF-1 1:1500), t-GSK3β (1:500, 
Cell Signaling), p-GSK3β (GSK3βY216, 1:500, Life Tech-
nologies), t-Akt (1:1000, Cell Signaling), p-Akt (Ser473, 
1:500, Santa Cruz) followed by HRP-tagged secondary 
antibodies (1:5000 Santa Cruz Biotechnology). Bands 
were visualized by enhanced chemiluminescence (ECL, 
PerkinElmer, Boston, MA) and analyzed with a quanti-
tative Versadoc XL imaging apparatus (BioRad). β-Actin 
(1:3000, Sigma) was used as the loading control.
Statistical analysis
All analyses were performed using GraphPad Prism 
(Version 5.0). Differences among means were assessed 
by one-way ANOVA with Dunnett’s post hoc test when 
compared to non-tg and by Tukey–Kramer when com-
paring tg groups. Two-way ANOVA with repeated meas-
ures followed by a Bonferroni multiple comparisons post 
hoc test was used for analyzing the interactions between 
groups and time. The null hypothesis was rejected at the 
0.05 level.
Results
Cerebrolysin treatment reduced tau 
hyper‑phosphorylation in 3R tau transgenic mouse 
without affecting total levels of 3R tau
To investigate the neuroprotective versus the therapeutic 
effects of CBL in a 3R tau tg mouse model of an orphan 
disorder namely PiD, mice were divided into two treat-
ment groups: those with a treatment start at 3 month of 
age (3–6 month group) and those beginning at 6 month 
of age (6–9  month group). The choice of these groups 
was based on our previous time course studies that have 
shown progressive tau pathology in this mouse model 
starting at 3 month of age [19]. As previously described, 
both groups of Line 13 mutant 3R tau tg mice displayed 
abundant 3R tau immunoreactivity in neuronal cells in 
the neocortex and hippocampus including pyramidal 
layers and dentate gyrus (Fig. 1) [19]. In the 3–6 month 
group, no 3R tau was detected in the non-tg mice treated 
with either vehicle or CBL (Fig. 1a). In the tg mice treated 
with vehicle or CBL similar numbers of 3R tau positive 
cells were detected in the neocortex and hippocampus 
(Fig.  1a, b). In the 6–9  month group overall there was 
abundant 3R tau accumulation in the tg mice while no 3R 
tau was detected in non-tg littermates (Fig. 1c). In the 3R 
tau tg mice, CBL treatment reduced the accumulation of 
3R tau in neuronal cell bodies and in the neuropil com-
pared to vehicle treatment (Fig. 1c, d). In the hippocam-
pus there were no significant effects of CBL compared to 
vehicle (Fig. 1c, d).
Next we analyzed the levels of tau phosphorylation 
with the PHF-1 antibody that is sensitive at detecting 
pathological forms of tau found in patients with PiD 
and in the 3R tau tg model. In the non-tg mice from the 
3–6 month group we observed mild immunoreactivity in 
the neuropil but no neuronal immunolabeling (Fig.  2a). 
In the 3R tau tg mice from the 3–6  month group there 
was abundant p-tau immunostaining of neuronal cell 
bodies and axons in the neocortex and hippocampus 
that was more abundant in the vehicle tg mice com-
pared to the CBL treated animals (Fig.  2a, b). Likewise, 
in the 6–9 month group there was greater levels of p-tau 
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immunoreactivity in neuronal cell and axons in the neo-
cortex and hippocampus of the vehicle-treated 3R tau tg 
with a significant reduction in both regions in animals 
treated with CBL (Fig. 2c, d).
To further verify these results by an independ-
ent method, immunoblot analysis was performed. As 
expected, in the 3–6 month group abundant 3R tau was 
detected in the tg mice as a triplet band at an estimated 
MW of 50–60 kDa (Fig. 3a). No bands were detected in 
the non-tg groups (Fig. 3a). The levels of 3R tau were sim-
ilar between the vehicle and CBL-treated tg mice (Fig. 3a, 
b). The p-tau band was identified in the 3R tau tg mice 
as doublet at an estimated MW of 50–60  kDa; a light 
single band was detected in the non-tg mice (Fig.  3a). 
The vehicle-treated tg mice displayed higher levels of 
p-tau immunoreactivity, levels were decreased in 3R tau 
Fig. 1 Immunocytochemical analysis of effects of CBL on levels of 3R Tau transgenic mice. a Immunocytochemistry with an antibody against 3R 
Tau in the 3–6 month group. b Image analysis of levels of 3R Tau immunoreactivity in the neocortex and hippocampus. c Immunocytochemistry 
with an antibody against 3R Tau in the 6–9 month group. d Image analysis of levels of 3R Tau immunoreactivity in the neocortex and hippocampus 
of the 6–9 month group. For analysis, N = 10 non-tg and N = 10 3R Tau tg mice from each age and treatment group. #P < 0.05 when compared to 
vehicle-treated tg mice control using one way ANOVA with Dunnet’s post hoc test
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tg mice treated with CBL (Fig. 3a, c). In the 6–9 month 
group there was more abundant 3R tau and p-tau 
immunoreactivity (compared to the 3–6  month group), 
detected in the tg mice as a triplet band at an estimated 
MW of 50–60 kDa (Fig. 3d). No bands were detected in 
the non-tg groups (Fig.  3d). The levels of 3R tau were 
similar between the vehicle and CBL-treated tg mice 
(Fig. 3d, e). The vehicle-treated tg mice displayed higher 
levels of p-tau immunoreactivity, levels were decreased in 
3R tau tg mice treated with CBL (Fig. 3d, f ).
Cerebrolysin treatment prevented and rescued the 
neurodegenerative pathology in 3R tau transgenic mice
The neurodegenerative pathology in the mice was inves-
tigated by immunocytochemistry and image analysis 
with antibodies against the neuronal marker, NeuN, and 
Fig. 2 Immunocytochemical analysis of effects of CBL on levels of p-tau in 3R tau transgenic mice. a Immunocytochemistry with an antibody 
against p-tau (PHF1) in the 3–6 month group. b Image analysis of levels of p-tau immunoreactivity in the neocortex and hippocampus. c Immuno-
cytochemistry with an antibody against p-Tau in the 6–9 month group. d Image analysis of levels of p-tau tau immunoreactivity in the neocortex 
and hippocampus of the 6–9 month group. For analysis, N = 10 non-tg and N = 10 3R Tau tg mice from each age and treatment group. *P < 0.05 
when compared to non-tg control using one way ANOVA with Dunnet’s post hoc test. #P < 0.05 when compared to vehicle-treated tg mice control 
using one way ANOVA with Dunnet’s post hoc test
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the astroglial marker, GFAP. In the 3–6 month group, as 
previously described, we observed in the vehicle-treated 
3R tau tg mice a reduction in the number of cells in the 
frontal cortex and in the dentate gyrus of the hippocam-
pus (Fig.  4a, b). Treatment with CBL was protective as 
the neuronal cell counts in both of these regions were 
similar in the non-tg groups and in the 3R tau tg treated 
with CBL (Fig. 4a, b). In the 6–9 month group, the loss 
of neurons in the neocortex and dentate gyrus of the 
vehicle-treated 3R tau tg mice was greater (Fig.  4c, d). 
Compared to the non-tg groups, there was an ameliora-
tion of the neuronal deficits in the CBL-treated 3R tau 
tg mice (Fig.  4c, d). These results were confirmed with 
MAP2, a second neuronal-specific marker (Fig. 4e, f ). As 
with the NeuN, MAP2 immunoreactivity in the dentate 
gyrus demonstrated neuronal loss in the vehicle-treated 
3R tau tg mice and vehicle-treated non-tg mice, this was 
observed in both the 3–6 and 6–9 month groups (Fig. 4e, 
f ). CBL treatment increased MAP2 immunoreactivity in 
the 3R tau tg mice, bringing it in line with that observed 
in the vehicle-treated non-tg mice (Fig. 4e, f ).
In these tg mice the neuronal loss is accompanied by 
astrogliosis. In the 3–6  month group there was some 
astrogliosis in the neocortex of the vehicle treated 3R tau 
tg mice compared to the non-tg mice (Fig. 5a, b). Treat-
ment with CBL rescued this effect in the neocortex of the 
3R tau tg mice (Fig. 5a, b). In the 6–9 month group there 
was astrogliosis in the neocortex and hippocampus of the 
vehicle treated 3R tau tg mice compared to the non-tg 
mice (Fig. 5c, d). Treatment with CBL partially reduced 
astrogliosis in the 3R tau tg mice (Fig. 5c, d). There was 
no significant difference between CBL-treated non-tg 
mice and 3R tau tg mice treated with CBL.
Cerebrolysin treatment ameliorated the behavioral deficits 
in 3R tau transgenic mice
To investigate the functional effects of CBL in the 3R tau 
tg mice behavioral analysis was performed in the open 
Fig. 3 Western blot analysis of effects of CBL on levels of tau in 3R tau transgenic mice a Representative immunoblots of samples from the 
3–6 month group analyzed with antibodies against 3R Tau tTau and p-tau (PHF1). b, c Image analysis of levels of 3R Tau and ratio of p-tau/tTau in 
the brains of mice from the 3–6 month group. d Representative immunoblots of samples from the 6–9 month group analyzed with antibodies 
against 3R Tau, tTau and p-tau (PHF1). e, f Image analysis of levels of 3R tau and p-tau/tTau in the brains of mice from the 6–9 month group. For 
analysis, N = 10 non-tg and N = 10 3R Tau tg mice from each age and treatment group. *P < 0.05 when compared to non-tg control using one way 
ANOVA with Dunnet’s post hoc test. #P < 0.05 when compared to vehicle-treated tg mice control using one way ANOVA with Dunnet’s post hoc test
(See figure on next page.)
Fig. 4 Analysis of NeuN cell counts in 3R tau transgenic mice treated with CBL. a Immunocytochemistry with an antibody against NeuN in the 
3–6 month group. b Stereological analysis with the dissector method to estimate the numbers of NeuN positive cells in the neocortex and hip-
pocampus in the 3–6 month group. c Immunocytochemistry with an antibody against NeuN in the brains of the 6–9 month group. d Stereological 
analysis with the dissector method to estimate the numbers of NeuN positive cells in the neocortex and hippocampus in the 6–9 month group. For 
analysis, N = 10 non-tg and N = 10 3R Tau tg mice from each age and treatment group. *P < 0.05 when compared to non-tg control using one way 
ANOVA with Dunnet’s post hoc test. #P < 0.05 when compared to vehicle-treated tg mice control using one way ANOVA with Dunnet’s post hoc test
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field, nesting test, and water maze. In the 3–6  month 
group analysis in the open field showed a trend toward 
increased total activity and rearing in the 3R tg tau mice, 
but no statistically significant differences were observed 
among the four groups (Fig. 6a, b). However, in the nest-
ing test, the vehicle treated 3R tau tg mice displayed 
a profound reduction in the ability to build the nest 
(Fig. 6c). Treatment with CBL partially rescued the alter-
ations in this behavior in the 3R tau tg mice (Fig. 6c). In 
the 6–9 month group in the open field no statistically sig-
nificant differences among the four groups were detected 
(Fig. 6d, e). In the nesting test, the vehicle treated 3R tau 
tg mice displayed significant alterations that were not 
fully rescued by CBL treatment (Fig. 6f ). Next analysis of 
Fig. 5 Analysis of astrogliosis in 3R Tau transgenic mice treated with CBL a Immunocytochemistry with an antibody against GFAP in the 3–6 month 
group. b Computer aided image analysis of levels of GFAP immunoreactivity in the neocortex and hippocampus in the 3–6 month group. c Immu-
nocytochemistry with an antibody against GFAP in the brains of the 6–9 month group. d Computer aided image analysis of levels of GFAP immu-
noreactivity in the neocortex and hippocampus in the 6–9 month group. For analysis, N = 10 non-tg and N = 10 3R Tau tg mice from each age 
and treatment group. *P < 0.05 when compared to non-tg control using one way ANOVA with Dunnet’s post hoc test. #P < 0.05 when compared to 
vehicle-treated tg mice control using one way ANOVA with Dunnet’s post hoc test
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memory and spatial learning was performed in the water 
maze. In the 3–6 month group compared to the non-tg 
mice the vehicle treated 3R tau tg mice displayed defi-
cits in spatial learning acquisition in the hidden platform 
segment of the test (Fig. 7a). In contrast, CBL treatment 
prevented these deficits in the 3R tau tg mice (Fig.  7a). 
Memory retention in the probe test showed that com-
pared to non-tg mice the vehicle treated 3R tau tg mice 
expended less time in the target quadrant (Fig. 7b), treat-
ment with CBL rescued this deficit in the 3R tau tg mice 
(Fig. 7b), which performed similar to the non-tg control 
groups (Fig.  7b). Visual success was comparable among 
the four groups of mice for the 3–6 month group (Fig. 7c). 
Next, analysis of memory and spatial learning was per-
formed in the 6–9 month group. Compared to the non-tg 
mice, the vehicle treated 3R tau tg mice displayed deficits 
in spatial learning acquisition in the hidden platform seg-
ment of the test (Fig.  7d), CBL did not fully ameliorate 
these deficits (Fig.  7d). Memory retention in the probe 
test showed that compared to non-tg mice the vehicle 
treated 3R tau tg mice expended less time in the target 
quadrant (Fig. 7e), however, here CBL treatment amelio-
rated the deficits in the 3R tau tg mice (Fig.  7e), which 
performed similar to the non-tg control groups (Fig. 7e). 
Visual success score was higher in the non-tg compared 
to the 3R tau tg mice (Fig. 7f ), indicating that in this older 
age group some visual impairment is present that might 
account for the lack of effects of CBL in the hidden seg-
ment of the platform test.
Cerebrolysin effects on 3RTau phosphorylation might be 
mediated via Akt/GKS3β
We have previously shown that CBL rescues the hyper-
activation of GSK3β in other transgenic models [15, 17], 
in order to examine the mechanisms through which CBL 
might reduce the hyper-phosphorylation of 3R Tau and 
ameliorate the neurodegenerative pathology we analyzed 
levels of GSK3β and Akt by immunoblot. We found that 
there was increased activation of p-GSK3β (Y216) in the 
vehicle-treated 3R Tau tg mice compared to non-tg con-
trols Fig.  8a, b), and therefore the ratio of p-GSK3β to 
t-GSK3β was higher (Fig. 8b). In contrast, treatment with 
CBL reduced p-GSK3β (Y216) and decreased the ratio 
of p-GSK3β to total (Fig.  8a, b). Next we analyzed Akt 
and found that there was decreased activation of p-Akt 
(Ser473) in the vehicle treated 3R Tau tg mice compared 
to non-tg controls (Fig. 8a, c), and therefore the ratio of 
p-Akt to total was lower (Fig.  8c). Treatment with CBL 
increased p-Akt (Ser473) and increased the ratio of p-Akt 
to total (Fig. 8a, c). Therefore, the neuroprotective effects 
of CBL in the 3R Tau tg mice might be related to regula-
tion of the Akt/GSK3β axis.
Fig. 6 Effects of CBL treatment in behavioral alterations in 3R Tau transgenic mice. Mice were evaluated for context-dependent learning in an open 
field area using a Kinder SmartFrame Cage Rack Station activity monitor system. a, b Levels of total activity and rearing in the cage in the 3–6 month 
group. c Nesting behavior in the cage of the 3–6 month group. d, e Levels of total activity and rearing in the cage in the 6–9 month group. f Nesting 
behavior in the cage of the 6–9 month group. For analysis, N = 10 non-tg and N = 10 3R Tau tg mice from each age and treatment group. *P < 0.05 
when compared to non-tg control using one way ANOVA with Dunnet’s post hoc test. #P < 0.05 when compared to vehicle-treated tg mice control 
using one way ANOVA with Dunnet’s post hoc test
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Discussion
In the present study, we investigated the neuropro-
tective versus therapeutic effects of CBL at rescuing 
pathology in mutant 3R Tau in tg mouse that models 
aspects of the pathogenesis in PiD. We found that early 
adminstration of CBL (at 3 month of age, for 3 months) 
resulted in decreased p-tau and completely rescued 
the neurodegenerative pathology and behavioral defi-
cits, although levels of 3R tau were not affected by the 
treatment. When CBL treatment occurred at a more 
advanced stage (6 month old mice) we still observed that 
this neurotrophic peptide mixture was able to reduce the 
levels of p-tau and ameliorated the neurodegenerative 
pathology, however only partially rescued the behavioral 
Fig. 7 Effects of CBL on learning memory in the water maze in 3R Tau tg mice. a Water maze testing presented as distance traveled to find the 
platform, respectively in the 3–6 month group. During the cued portion of the test both the vehicle and CBL treated non-tg and 3R tau tg mice 
performed as expected. However during the hidden portion of the test, the vehicle treated 3R tau tg mice went a farther distance to find the 
platform compared to the non-tg, CBL prevented these effects. b At day 8, during the probe portion of the test (with platform removed) memory 
retention was evaluated in the 3–6 month group. c In the 3–6 month group, probe test with the visual platform confirmed that no visual altera-
tions were detected. d Water maze testing presented as distance traveled to find the platform in the 6–9 month group. During the cued portion of 
the test both the vehicle and CBL treated non-tg and 3R tau tg mice performed as expected. However during the hidden portion of the test, the 
vehicle treated 3R Tau tg mice went a farther distance to find the platform compared to the non-tg. e At day 8, during the probe portion of the test 
(with platform removed) memory retention was evaluated in the 6–9 month group. f In the 6–9 month group, probe test with the visual platform 
showed visual alterations in the 3R tau tg group. For analysis, N = 10 non-tg and N = 10 3R Tau tg mice from each age and treatment group. 
*P < 0.05 when compared to non-tg control using one way ANOVA with Dunnet’s post hoc test. #P < 0.05 when compared to vehicle-treated tg 
mice control using one way ANOVA with Dunnet’s post hoc test
Fig. 8 Western blot analysis of effects of CBL on levels of Akt/GSK3β in the 3R Tau transgenic mice. a Representative immunoblots of samples from 
the 6–9 month group analyzed with antibodies against p-GSK3β (Y216), t-GSK3β, t-Akt and p-Akt (Ser473). b, c Image analysis of the ration between 
p-GSK3β (Y216) and total and p-Akt (Ser473) and total respectively. For analysis, N = 10 non-tg and N = 10 3R Tau tg mice from each age and 
treatment group. *P < 0.05 when compared to non-tg control using one way ANOVA with Dunnet’s post hoc test. #P < 0.05 when compared to tg 
control using one way ANOVA with Tukey post hoc test
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deficits. These results in the 3R tau tg mice are consist-
ent with previous studies showing that CBL rescues the 
neurodegenerative pathology associated with p-tau accu-
mulation. However in previous studies we investigated 
the effects of CBL at rescuing pathology associated with 
mutant 4R tau over-expression (AAV-mediated) in APP 
tg mice [16] or in crosses between mutant 4R tau tg and 
GSK3β tg mice [17]. In the bigenic mice, CBL treatment 
reduced the accumulation of p-Tau, ameliorated the neu-
rodegenerative pathology, decreased Drp-1 and p-Drp-1 
expression, and returned mitochondria to characteristics 
comparable to non-tg mice [17].
The precise mechanisms of action of CBL are unknown, 
however the rescue effects of CBL were likely related 
its ability to regulate levels of p-tau rather than levels of 
total tau (either 3R or 4R tau) [24]. This suggests that, 
at least in part, the neuroprotective and neurotrophic 
effects of CBL might be associated with its ability to reg-
ulate CDK5 and GSK3β activity. Both of these kinases 
have been previously shown to play an important role in 
hyper-phosphorylating tau [25–27] and mediating the 
neuropathology in models of AD and FTD [28, 29]. We 
have previously shown that the CBL neurotrophic pep-
tide mixture is capable of reducing behavioral deficits 
in an APP tg mouse model of AD-like pathology [13] by 
blocking CDK5 and GSK3β [16], resulting in decreased 
APP maturation and Aβ biosynthesis [30], increased 
neurogenesis [15] and synaptic formation [13]. Further 
supporting a role of this pathway a recent in vitro study 
showed that CBL protects neuronal cell lines from the 
neurotoxic effects of CoCl2 via regulation of GSK3β acti-
vation [31]. Interestingly, tau hyper-phosphorylation in 
PiD [32, 33] as well as in our model [19] is likely associ-
ated with GSK3β.
Pick’s disease belongs to the FTLD-tau with Picks 
bodies as defined by the working group [34–36]. Pick’s 
disease is a rare cause of dementia in the elderly, while 
some anti-depressants such as selective serotonin reup-
take inhibitors have been shown to ameliorate some of 
the symptoms and obsessive–compulsive behaviors asso-
ciated with PiD, there are currently no known disease-
modifying treatments available. Various experimental 
therapeutical approaches for this and other related tau-
pathies are under consideration and include down-regu-
lation of MAPT with anti-sense or siRNA approaches or 
pharmacological manipulations that reduce the expres-
sion of MAPT or kinase inhibitors that will block tau 
hyper-phosphorylation or stabilize the microtubular 
organization of the neurons [37]. Reducing tau hyper-
phosphorylation through the inhibition of selective tau 
kinases could improve tau interactions with microtubules 
and maybe reduce tau aggregation. Other approaches 
include reducing tau–tau interactions that result in 
oligomerization and fibril formation, mitigating the for-
mation of potentially neurotoxic tau species, and enhanc-
ing degradation of pathological tau through increasing 
clearance mechanisms [37]. Finally, a new provocative 
approach is to reduce the accumulation and propagation 
of tau utilizing specific monoclonal antibodies against 
various tau species [38–41].
Conclusions
In summary, in the present study we found that although 
the levels of total 3R tau were unchanged, CBL reduced 
the levels of hyper-phosphorylated tau in both groups of 
mice. This was accompanied by reductions in the neuro-
degenerative pathology in both groups and by improve-
ments in the behavioral deficits in the younger group. 
These results suggest that CBL might be beneficial in 
orphan disease taupathies such as PiD.
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